China’s NMPA grants greater access to rheumatology biosimilars

Center for Biosimilars

22 March 2022 - Since the start of 2022, China’s National Medicinal Products Agency has made strides to increase greater access to biosimilar products for various rheumatic conditions, including 3 biosimilar approvals and 1 biosimilar receiving an expanded indication.

China has been an emerging market for quite some time, having its first biosimilar approval in February 2019, which was a rituximab biosimilar (Hanlikon) developed by Henlius Fuhong Henlius referencing Rituxan.

Read Center for Biosimilars article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Regulation , Biosimilar , China